UBS Group AG - CHINA SXT PHARMACEUTICALS IN ownership

CHINA SXT PHARMACEUTICALS IN's ticker is SXTC and the CUSIP is G2161P108. A total of 7 filers reported holding CHINA SXT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
UBS Group AG ownership history of CHINA SXT PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2020$18,000
-45.5%
55,184
-59.5%
0.00%
Q3 2020$33,000
-50.0%
136,125
+9.1%
0.00%
Q2 2020$66,000
+500.0%
124,770
+523.8%
0.00%
Q1 2020$11,00020,000
+199900.0%
0.00%
Q4 2019$0
-100.0%
10
-99.5%
0.00%
Q2 2019$7,000
-53.3%
1,971
-10.9%
0.00%
Q1 2019$15,0002,2110.00%
Other shareholders
CHINA SXT PHARMACEUTICALS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Hudson Bay Capital Management LP 2,228,517$546,0000.01%
BEAM WEALTH ADVISORS, INC. 17,000$4,0000.00%
HRT FINANCIAL LP 328,435$80,0000.00%
Virtu Financial LLC 21,377$5,0000.00%
UBS Group AG 136,125$33,0000.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
ACADIAN ASSET MANAGEMENT LLC 56,253$14,0000.00%
ExodusPoint Capital Management, LP 45,052$11,0000.00%
Renaissance Technologies 304,674$75,0000.00%
Hudock, Inc. 5,000$1,0000.00%
View complete list of CHINA SXT PHARMACEUTICALS IN shareholders